Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.51 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.51 |
| ▸ | P2RY10 | O00398 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10931796 | 0.82 | LPAR3 (0.46) | LPAR3LPAR2LPAR1 | |
| SCHEMBL1689951 | 0.77 | LPAR3 (0.56) | LPAR3LPAR2LPAR1P2RY10SLC6A5 | |
| SCHEMBL1689992 | 0.76 | LPAR3 (0.55) | LPAR3LPAR2LPAR1P2RY10SLC6A5 | |
| Elaidylphosphocholine SCHEMBL12235518 | 0.75 | LPAR3 (0.60) | LPAR3LPAR2LPAR1P2RY10MEN1 | |
| Erufosine SCHEMBL14448104 | 0.75 | LPAR3 (0.60) | LPAR3LPAR2LPAR1P2RY10MEN1 | |
| Erufosine SCHEMBL14447882 | 0.75 | LPAR3 (0.60) | LPAR3LPAR2LPAR1P2RY10MEN1 | |
| Elaidylphosphocholine SCHEMBL515227 | 0.75 | LPAR3 (0.60) | LPAR3LPAR2LPAR1P2RY10MEN1 | |
| SCHEMBL9027644 | 0.75 | LPAR3 (0.60) | LPAR3LPAR2LPAR1P2RY10MEN1 | |
| SCHEMBL17817487 | 0.75 | LPAR3 (0.60) | LPAR3LPAR2LPAR1P2RY10MEN1 | |
| SCHEMBL14447825 | 0.75 | LPAR3 (0.60) | LPAR3LPAR2LPAR1P2RY10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331280-A1 | Modulation of the Phospholipase A2 Pathway as a Therapeutic | PARIS DANIEL C | 2010-12-30 | — | — | US | claimed |
| WO-2000002561-A1 | MODULATION OF THE PHOSPHOLIPASE A2 PATHWAY AS A THERAPEUTIC | UNIVERSITY OF SOUTH FLORIDA (US) | 2000-01-20 | — | — | WO | claimed |
| EP-1469859-B1 | Use of polyunsaturated ketones for the treatment of psoriasis | AVEXXIN AS (NO) | 2011-11-30 | — | — | EP | disclosed |
| US-20090130029-A1 | GLYCEROL ETHERS VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FOAMIX LTD. (IL) | 2009-05-21 | — | — | US | disclosed |
| US-7049079-B1 | Coupling factor 6 inhibitor and potentiator and use thereof | DAIICHI SUNTORY PHARMA CO.,LTD. (JP) | 2006-05-23 | — | — | US | disclosed |
| WO-2002000924-A2 | VIRAL PHOSPHOLIPASE A2 ENZYMES, ANTI-VIRAL AGENTS AND METHODS OF USE | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2002-01-03 | — | — | WO | disclosed |
| EP-1132092-A1 | COUPLING FACTOR 6 INHIBITOR AND POTENTIATOR AND USE THEREOF | SUNTORY LIMITED (JP) | 2001-09-12 | — | — | EP | disclosed |